• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Caym. Inds·Consumer Cyclical·6431.TW
Share

Kuangli Bio-Tech Holdings Co., Ltd. Stocks

NT$ 16.35Last Updated 06.10.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

NT$ 52.23M

NT$ 16.35
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Kuangli Photoelectric Technology Co., Ltd. specializes in the production and distribution of cover lens panels tailored for a wide array of electronic devices. These critical components are integrated into numerous products, including protective screens for mobile phones and laptops, cameras, decorative elements, buttons, and touch panels for tablet PCs and other consumer electronics. Additionally, their portfolio encompasses tempered glass, high-definition media players, digital video recorders (DVs), digital cameras, various home appliances, portable media players (MP3/MP4), vehicle recording devices (dashcams), lampshades, and medical instrumentation. The company commenced operations in 2002 and is headquartered in Kunshan, China.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

10.10.2026 06:47

Moderna hits four-year high as NYT reports U.S. cancer vaccine effort

10.10.2026 04:58

Palantir shares hit a new high: Barclays followed Goldman in recommending a buy

10.10.2026 04:25

Apple has cut orders for parts for the new iPhones, according to media reports. Was demand lower than expected?

10.10.2026 03:01

An analyst sees Starlink's transition into a cell phone carrier as a problem for Apple and Samsung

10.10.2026 02:09

Iran threatens to target ships beyond Hormuz as oil exports out of Persian Gulf rise

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026